AMAO76 Alleviates the Pressure for Amakem Therapeutics

Jack Elands, CEO for Amakem, talks about his company’s focus on a localized drug action platform, and details the company’s feature glaucoma product to lower intraocular pressure designated, AMAO76 rokinase inhibitor.


Jack Elands

Jack Elands

Dr. Jack Elands has been the CEO of Amakem since its inception. Before, Jack was CBO of Silicos, an informatics based biotechnology company, CEO of Vitec, a specialty biotech company focused on antimicrobial products and VP of Business Development at Sidec, a biotech focused on developing protein based drugs.

View Full Profile